Email Updates

You are here

Home»Media

AVAC in the News

  • Young Women Prefer Vaginal Ring as HIV Prevention

    When given the option, adolescent girls and young women in Africa overwhelmingly opted to use either a drug-eluting vaginal ring or oral pre-exposure prophylaxis (PrEP) to protect against HIV infection, a researcher reported.

    February 18, 2022
    Microbicides, PrEP
    MedPage Today

  • What’s an Endpoint?

    Understand what matters most about clinical trial endpoints for both advocates and researchers. This conversation includes Jeanne Baron, the host of Px Pulse; Matthew Rose, a director at Global Health Strategies; Dave Glidden, a professor of biostatistics at the University of California at San Francisco; Erica Lessem, a senior strategist for the New York City Department of Health and Mental Hygiene; and Meagan O’Brien, the senior medical director of early clinical development and clinical experimental sciences at Regeneron.

    February 14, 2022
    General
    POZ

  • Research on Transgender People Must Benefit Transgender People

    As transgender people working in HIV research and public health, we express concern over the exploitation of transgender communities in academic research. Articles published in The Lancet have compelled our response, but in the spirit of calling our colleagues in rather than out, we are responding to the broader practice of studying transgender communities as so-called subjects of academic intrigue rather than real people with urgent health needs.

    February 12, 2022
    The Lancet

  • A New HIV Vaccine Is in Phase One Trials. But Scientists Aren’t Holding Their Breath Just Yet

    Future historians studying the 2020s may disagree about many things, but it is safe to assume all of them will agree that the COVID-19 pandemic was transformative. When it comes to humanity's ongoing war against infectious diseases, this pandemic accelerated development of a new vaccine platform known as mRNA technology, one that scientists believe could some day be used against everything from malaria and tuberculosis to all strains of influenza.

    February 10, 2022
    HIV Vaccine
    Salon

  • Mitigation Strategies To Safely Conduct HIV Treatment Research in the Context of COVID-19

    The International AIDS Society convened a multidisciplinary committee of experts in December 2020 to provide guidance and key considerations for the safe and ethical management of clinical trials involving people living with HIV (PLWH) during the SARS-CoV-2 pandemic. This consultation did not discuss guidance for the design of prevention studies for people at risk of HIV acquisition, nor for the programmatic delivery of antiretroviral therapy (ART).

    February 9, 2022
    Treatment
    JIAS

  • HIV Prevention: Financial Slack for Research

    Simple effect of COVID-19 or long-term trend? In 2020, HIV prevention research saw a notable drop in funding globally, a report released in December by AVAC reveals. Figures to be interpreted with caution, as research is advancing rapidly.

    January 17, 2022
    General
    Transversal

  • Injectable PrEP and COVID Show We’re All in This Together

    Just before Christmas, the US Food and Drug Administration (FDA) announced that it had approved an injectable formulation of the HIV drug cabotegravir for use as PrEP. The drug, to be given as an injection every two months, will be branded as Apretude in the US. Although FDA approval came earlier than expected, they could have hardly rejected it.

    January 7, 2022
    General, Microbicides, PrEP, Treatment
    aidsmap

  • Funding for Research in HIV Prevention Continues to Drop

    Financial support for the research and development (R&D) of HIV prevention declined in 2020, marking a drop for the second year in a row and continuing an eight-year trend of either decreased or flat funding, according to the latest annual report on the topic from AVAC, a global organization focused on HIV prevention.

    December 28, 2021
    PrEP
    POZ

  • FDA Approves First Long-Acting Injectable to Prevent HIV Infection

    The first long-acting injectable for HIV prevention has now been approved for use, the FDA announced on Monday. Long-acting injectable cabotegravir (CAB-LA, branded as Apretude) is administered as a monthly injection for the first 2 months, then every 2 months afterwards. It is the first long-acting injectable for pre-exposure prophylaxis (PrEP). The drug is approved for adults and adolescents weighing at least 77 lb.

    December 22, 2021
    PrEP
    MedPage Today

  • Although PrEP is Largely Underutilized, Developing Strategies Aim to Increase Initiation

    There had been more 200,000 pre-exposure prophylaxis (PrEP) initiations in North America from 2016-2020, according to data from the AVAC earlier this year. While the US is highly contributory to the gradually increasing rate of HIV-risk persons gaining access to PrEP annually, it’s not enough to consider the work accomplished on a national scale.

    December 22, 2021
    PrEP
    Contagion Live

Pages